» Articles » PMID: 23288052

Molecular Mechanisms of Fibrosis-associated Promotion of Liver Carcinogenesis

Overview
Journal Toxicol Sci
Specialty Toxicology
Date 2013 Jan 5
PMID 23288052
Citations 43
Authors
Affiliations
Soon will be listed here.
Abstract

Hepatocellular carcinoma (HCC) mostly develops in patients with advanced fibrosis; however, the mechanisms of interaction between a genotoxic insult and fibrogenesis are not well understood. This study tested a hypothesis that fibrosis promotes HCC via a mechanism that involves activation of liver stem cells. First, B6C3F1 mice were administered diethylnitrosamine (DEN; single ip injection of 1mg/kg at 14 days of age). Second, carbon tetrachloride (CCl(4); 0.2ml/kg, 2/week ip starting at 8 weeks of age) was administered for 9 or 14 weeks to develop advanced liver fibrosis. In animals treated with DEN as neonates, presence of liver fibrosis led to more than doubling (to 100%) of the liver tumor incidence as early as 5 months of age. This effect was associated with activation of cells with progenitor features in noncancerous liver tissue, including markers of replicative senescence (p16), oncofetal transformation (Afp, H19, and Bex1), and increased "stemness" (Prom1 and Epcam). In contrast, the dose of DEN used did not modify the extent of liver inflammation, fibrogenesis, oxidative stress, proliferation, or apoptosis induced by subchronic CCl(4) administration. This study demonstrates the potential role of liver stem-like cells in the mechanisms of chemical-induced, fibrosis-promoted HCC. We posit that the combination of genotoxic and fibrogenic insults is a sensible approach to model liver carcinogenesis in experimental animals. These results may contribute to identification of cirrhotic patients predisposed to HCC by analyzing the expression of hepatic progenitor cell markers in the noncancerous liver tissue.

Citing Articles

Oncogenic plasmid DNA and liver injury agent dictates liver cancer development in a mouse model.

Chiu V, Yee C, Main N, Stevanovski I, Watt M, Wilson T Clin Sci (Lond). 2024; 138(19):1227-1248.

PMID: 39254423 PMC: 11427747. DOI: 10.1042/CS20240560.


Co-delivery of camptothecin and MiR-145 by lipid nanoparticles for MRI-visible targeted therapy of hepatocellular carcinoma.

Rong J, Liu T, Yin X, Shao M, Zhu K, Li B J Exp Clin Cancer Res. 2024; 43(1):247.

PMID: 39215325 PMC: 11363558. DOI: 10.1186/s13046-024-03167-9.


Proteomic analysis of DEN and CCl-induced hepatocellular carcinoma mouse model.

Zhang Q, Liu Y, Ren L, Li J, Lin W, Lou L Sci Rep. 2024; 14(1):8013.

PMID: 38580754 PMC: 10997670. DOI: 10.1038/s41598-024-58587-6.


The value of CDC42 effector protein 2 as a novel prognostic biomarker in liver hepatocellular carcinoma: a comprehensive data analysis.

Kim H, Seo C, Kim J Osong Public Health Res Perspect. 2024; 14(6):451-467.

PMID: 38204425 PMC: 10788419. DOI: 10.24171/j.phrp.2023.0229.


SPINK1-induced tumor plasticity provides a therapeutic window for chemotherapy in hepatocellular carcinoma.

Man K, Zhou L, Yu H, Lam K, Cheng W, Yu J Nat Commun. 2023; 14(1):7863.

PMID: 38030644 PMC: 10687140. DOI: 10.1038/s41467-023-43670-9.


References
1.
Oishi N, Wang X . Novel therapeutic strategies for targeting liver cancer stem cells. Int J Biol Sci. 2011; 7(5):517-35. PMC: 3088875. DOI: 10.7150/ijbs.7.517. View

2.
Nault J, Zucman-Rossi J . Genetics of hepatobiliary carcinogenesis. Semin Liver Dis. 2011; 31(2):173-87. DOI: 10.1055/s-0031-1276646. View

3.
Ma S, Chan K, Hu L, Lee T, Wo J, Ng I . Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology. 2007; 132(7):2542-56. DOI: 10.1053/j.gastro.2007.04.025. View

4.
Graveel C, Jatkoe T, Madore S, Holt A, Farnham P . Expression profiling and identification of novel genes in hepatocellular carcinomas. Oncogene. 2001; 20(21):2704-12. DOI: 10.1038/sj.onc.1204391. View

5.
Cabre M, Camps J, Paternain J, Ferre N, Joven J . Time-course of changes in hepatic lipid peroxidation and glutathione metabolism in rats with carbon tetrachloride-induced cirrhosis. Clin Exp Pharmacol Physiol. 2000; 27(9):694-9. DOI: 10.1046/j.1440-1681.2000.03322.x. View